Instrument Inactif

Communiqués Impax Laboratories Inc Nasdaq

Actions

US45256B1017

Produits pharmaceutiques

Communiqués

10/06	Dispensary of Hope Launches "Hope Alliance" Campaign with Support from Amneal Pharmaceuticals	PR
08/06	Amneal And Kashiv File IPR Petition On Omalizumab Patent	AQ
05/06	Amneal Announces Full Study Population Interim Phase 4 ELEVATE-PD Results, Reinforcing Previously Reported Benefits of CREXONT® in Parkinson's Disease	GL
04/06	Amneal Announces U.S. FDA Approval of Romidepsin Injection Solution	GL
01/06	Amneal to Participate in Goldman Sachs 47th Annual Global Healthcare Conference 2026	GL
11/05	Amneal Agrees To Acquire Kashiv BioSciences For Total Payment Up To $1.1 Billion	AQ
08/05	Amneal Pharmaceuticals : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q)	PU
07/05	Amneal Reports First Quarter 2026 Financial Results	GL
22/04	Amneal Pharmaceuticals : Kashiv Biosciences Acquisition and Q1 2026 Financial Results	PU
22/04	Amneal: Q1 Earnings Snapshot	AQ
22/04	Kashiv BioSciences Agrees to Be Acquired by Amneal Pharmaceuticals to Create a Fully Integrated Global Biosimilar Leader	BU
22/04	Amneal Agrees to Acquire Kashiv BioSciences to Create Global Biosimilar Leader; Reports Strong Preliminary First Quarter 2026 Financial Results and Raises FY2026 Standalone Guidance	GL
20/04	Amneal Announces Additional Positive Interim Phase 4 ELEVATE-PD Results with CREXONT® for Parkinson’s Disease, Including Over 3 More Hours of Daily “Good On” Time When Switching from RYTARY®	GL
14/04	Amneal Launches First Two Respiratory Metered-Dose Inhalation Products in the U.S.	GL
09/04	Amneal Launches Bimatoprost Ophthalmic Solution, 0.01%	GL
07/04	Amneal to Report First Quarter 2026 Results on May 1, 2026	GL
07/04	Amneal Announces $2 Million Donation to Support Patient Access to Essential Medicines During Parkinson’s Awareness Month	GL
24/03	Amneal Pharmaceuticals : LLC Issues Voluntary Nationwide Recall of Magnesium Sulfate in Water for Injection, USP 4 g/100mL (NDC 70121-1720-3) due to a Product Mix-up with Tranexamic Acid in 0.7% Sodium Chloride Injection, 10 mg/mL	PU
05/03	Amneal to Participate in Upcoming Investor Conference	GL
02/03	Amneal Reports Fourth Quarter and Full Year 2025 Financial Results	AQ
27/02	Amneal Pharmaceuticals : Fourth Quarter 2025 Earnings Presentation	PU
27/02	Amneal: Q4 Earnings Snapshot	AQ
27/02	Amneal Reports Fourth Quarter and Full Year 2025 Financial Results	GL
28/01	Amneal Pharmaceuticals Added to S&P SmallCap 600® Index	GL
27/01	Amneal to Report Fourth Quarter and Full Year 2025 Results on February 27, 2026	GL